Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 1/2 1Phase 1 1

Status

Completed 5Terminated 4Recruiting 4Unknown 1Suspended 1Not yet recruiting 1

Sponsor Class

OTHER 2INDUSTRY 2

Study Type

Interventional 4

Sponsor

Cancer Type

Gynecologic 4Gastrointestinal 3Thoracic 2Head & Neck 1Breast 1

Conditions

Melanoma 23Neoplasm Metastasis 14Leukemia, Myeloid, Acute 11Carcinoma, Renal Cell 10Neoplasms 8Kidney Neoplasms 8Skin Neoplasms 5Recurrence 5Leukemia 5Carcinoma, Non-Small-Cell Lung 5Breast Neoplasms 5Ovarian Neoplasms 4Lymphoma, Non-Hodgkin 4Colorectal Neoplasms 4Precursor Cell Lymphoblastic Leukemia-Lymphoma 3Pancreatic Neoplasms 3Neuroblastoma 3Lymphoma, Follicular 3Congenital Abnormalities 3Carcinoma 3Uterine Cervical Neoplasms 2Triple Negative Breast Neoplasms 2Prostatic Neoplasms 2Myelodysplastic Syndromes 2Lymphoma, Large B-Cell, Diffuse 2Lymphoma, B-Cell, Marginal Zone 2Lymphoma 2Leukemia, Lymphocytic, Chronic, B-Cell 2Head and Neck Neoplasms 2Carcinoma, Merkel Cell 2

Interventions

Carboplatin 44Paclitaxel 43liposomal doxorubicin 23Topotecan 19Gemcitabine 18pembrolizumab 17Cyclophosphamide 17Bevacizumab 16Cisplatin 12niraparib 9olaparib 8fludarabine 7Taxes 7Docetaxel 7aldesleukin 6Nivolumab 6Doxorubicin 61-dodecylpyridoxal 6oregovomab 5fludarabine phosphate 5Peripheral Blood Stem Cell Transplantation 5Filgrastim 5rucaparib 4durvalumab 4avelumab 4Surgical Procedures, Operative 4Melphalan 4Ipilimumab 4Interleukin-2 4Etoposide 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Terminated × Ovarian Neoplasms × Interleukin-2 × Clear all
NCT05194735 2025-11-10

Phase I/II Study of Autologous T Cells to Express T-Cell Receptors (TCRs) in Subjects With Solid Tumors

Alaunos Therapeutics

Phase 1/2 Terminated
8 enrolled 12 charts
GastrointestinalGynecologicThoracic

Adenocarcinoma of Lung, Carcinoma, Non-Small-Cell Lung, Ovarian Neoplasms, Pancreatic Neoplasms, Colorectal Neoplasms, Endometrial Neoplasms, Cholangiocarcinoma

NCT03610490 2025-04-17

Autologous Tumor Infiltrating Lymphocytes MDA-TIL in Treating Patients With Recurrent or Refractory Ovarian Cancer, Colorectal Cancer, or Pancreatic Ductal Adenocarcinoma

M.D. Anderson Cancer Center

Phase 2 Terminated
16 enrolled 11 charts
GastrointestinalGynecologic

Ovarian Neoplasms, Colorectal Neoplasms

NCT05395052 2023-09-21

FT536 Monotherapy and in Combination With Monoclonal Antibodies in Advanced Solid Tumors

Fate Therapeutics

Phase 1 Terminated
5 enrolled
BreastGastrointestinalGynecologicHead & NeckThoracic

Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Head and Neck Neoplasms, Ovarian Neoplasms, Pancreatic Neoplasms, Colorectal Neoplasms

NCT00652899 2017-12-28

Allogeneic Natural Killer Cells in Patients With Recurrent Ovarian Cancer, Fallopian Tube, and Primary Peritoneal Cancer

Masonic Cancer Center, University of Minnesota

Phase 2 Terminated
14 enrolled 9 charts
Gynecologic

Carcinoma, Ovarian Epithelial, Fallopian Tube Neoplasms, Ovarian Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡